Schering Corporation

James E Patrick

Joel A Sequeira

Imtiaz A Chaudry

Francis M Cuss

Nagamani Nagabhushan

Keith B Nolop

Mitchell Cayen

Kevin B Alton

Swapan K Chowdhury

Anima Ghosal

Shmuel Zbaida

Andrew William Stamford

Craig D Boyle

Harry R Davis

Wenqing Feng

Robert M Iannucci

Wei Tong

Mark A Wirth

The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. Further disclosed are methods of treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the above compound, wherein the physiological disorder, symptom or disease is a urogenital, cardiovascular, cerebrovascular or peripheral vascular disorder, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, a respiratory tract disorder such as an allergic condition associated with atopy, pulmonary hypertension, an ischemic heart disorder, impaired glucose tolerance, diabetes and its related complication, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, a glomerular disorder, renal insufficiency, nephritis, a tubular interstitial disorder, an autoimmune disorder, glaucoma, intestinal motility, cachexia or cancer.

Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

Hypocholesterolemic substituted 2-azetidinone compounds of the formula:are disclosed, as well as a methods of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

Substituted 2-azetidinones useful as hypocholesterolemic agents

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

Use of mometasone furoate for treating upper airway diseases

Use of mometasone furoate for treating airway passage and lung diseases

Use of mometasone furoate for treating lower airway passage and lung

Use of mometasone furoate for treating upper airway passage diseases

Growing community of inventors

Belle Meade, NJ, United States of America

James E Patrick